These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30132911)

  • 1. Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care.
    Jimenez-Marco T; Garcia-Recio M; Girona-Llobera E
    Transfusion; 2018 Aug; 58(8):1881-1889. PubMed ID: 30132911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: focusing on neonates.
    Jimenez-Marco T; Garcia-Recio M; Girona-Llobera E
    Transfusion; 2019 Dec; 59(12):3580-3588. PubMed ID: 31587287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
    Mirasol Clinical Evaluation Study Group
    Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
    Ambruso DR; Thurman G; Marschner S; Goodrich RP
    Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation and thrombus stability on collagen.
    Terada C; Shiba M; Nagai T; Satake M
    Transfusion; 2017 Jul; 57(7):1772-1780. PubMed ID: 28417457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
    Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
    Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.
    Ballester-Servera C; Jimenez-Marco T; Morell-Garcia D; Quetglas-Oliver M; Bautista-Gili AM; Girona-Llobera E
    Blood Transfus; 2020 Jul; 18(4):280-289. PubMed ID: 32530405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience.
    Girona-Llobera E; Jimenez-Marco T; Galmes-Trueba A; Muncunill J; Serret C; Serra N; Sedeño M
    Transfusion; 2014 Jan; 54(1):158-68. PubMed ID: 23656485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
    Reid S; Johnson L; Woodland N; Marks DC
    Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
    Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
    Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
    Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD
    Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective.
    Li JW; Brecher ME; Jacobson JL; Harm SK; Chen D; El-Gamil A; Dobson A; Mintz PD
    Transfusion; 2017 Oct; 57(10):2321-2328. PubMed ID: 28703862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
    Terada C; Shiba M; Satake M; Tadokoro K
    Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.
    Drawz SM; Marschner S; Yañez M; García de Coca A; Feys HB; Deeren D; Coene J
    Transfusion; 2015 Jul; 55(7):1745-51. PubMed ID: 25702711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
    Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
    Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin αIIbβ3 activation.
    Terada C; Mori J; Okazaki H; Satake M; Tadokoro K
    Transfusion; 2014 Jul; 54(7):1808-16. PubMed ID: 24506417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.
    Schubert P; Coupland D; Culibrk B; Goodrich RP; Devine DV
    Transfusion; 2013 Dec; 53(12):3164-73. PubMed ID: 23521225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.